As part of our strategic goal of achieving future designation as an NCI Comprehensive Cancer Center, MCI has created an Executive Advisory Board, which serves to provide advice to the Director, USA Mitchell Cancer Institute (MCI), and President, University of South Alabama, on all matters pertinent to the oncology healthcare and research missions of the MCI, particularly in regard to achieving NCI designation.
An external expert Advisory Board is a requirement for any prospective or extant NCI Comprehensive Cancer Center. Prospective NCI Centers are substantially judged by the quality of the external advisors that they attract and engage. Creation of this board will immediately and substantially enhance:
• The scientific and clinical credibility of the MCI
• Financial viability of the MCI clinical services business
• Competitiveness for federal and other national grant funding of cancer-related research
• Competitiveness, national/international networking for and access to philanthropic support of MCI programs
• Competitiveness, national/international networking for and access to top-tier funding opportunities from pharmaceutical and biotechnology industries
• Competitiveness, national/international networking for continued recruitment of highest quality oncology physicians and cancer researchers to the MCI faculty
• Partnerships with affiliate institutions throughout region that are mutually beneficial and enhance oncology care and research
Alex Adjei, M.D., Ph.D., FACP (Executive Advisory Board Chair)
Director, Early Cancer Therapeutics Program
Director, Global Oncology
Dr. Alex Adjei received his M.D. from the University of Ghana Medical School in Legon, Ghana, and also holds a Ph.D. from the University of Alberta, in Edmonton, Alberta, Canada. He has served as Senior Vice President of Clinical Research and Professor and Chair, Department of Medicine at Roswell Park Cancer Institute and School of Medicine and Biomedical Sciences at State University of New York at Buffalo. A leading expert in the field of lung cancer, Dr. Adjei’s areas of research interest include the development of novel agents for the therapy of solid tumors. He is a Board Certified Diplomate in Internal Medicine and Medical Oncology from the American Board of Internal Medicine.
Yusuf Hannun, M.D.
Director, Stony Brook Cancer Center
Vice Dean for Cancer Medicine
Joel Strum Kenny Professor in Cancer Research
Stony Brook University Medical Center
Stony Brook, New York
Dr. Yusuf Hannun earned his MD degree with distinction in 1981 from the American University in Beirut, Lebanon. At American University, he completed an internship and residency in internal medicine. In 1986 he immigrated to the United States to serve a fellowship in hematology and oncology at Duke University, where he rose to become the Wayne Rundles Professor of Oncology, director of the program in molecular medicine, and associate director of the Duke Comprehensive Cancer Center. He was named director of Stony Brook Cancer Center in March 2012 after a decade of leadership at the Medical University of South Carolina's Hollings Cancer Center in Charleston, S.C.
Jay Loeffler, M.D.
Herman and Joan Suit Professor of Radiation Oncology
Department of Radiation Oncology, Harvard Medical School
Chair, Radiation Oncology, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center
A leading expert on Radiosurgery and Radiation Injuries, Dr. Jay Loeffler received his M.D. from the Warren Alpert Medical School Of Brown University, and followed that with a residency at Harvard Joint Center and a fellowship at Harvard School of Public Health. With a special research interest in proton therapy, Dr. Loeffler is Professor of Radiation Oncology at Harvard Medical School, and is the Chair of Radiation Oncology at Massachusetts General Hospital, Dana-Farber / Harvard Cancer Center.
Joyce O’Shaughnessy, M.D.
Co-Chair, Breast Cancer Research
Medical Director, US Oncology Research
Baylor-Charles A. Sammons Cancer Center
Texas Oncology and The US Oncology Network
A leading expert on Adjuvant Chemotherapy, Dr. Joyce O’ Shaughnessy received her M.D. from Yale University School of Medicine, and followed that with a residency at s Massachusetts General Hospital and a fellowship at the National Cancer Institute. Currently, Dr. O’ Shaughnessy has served as Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center. With a special research interest in Breast Cancer, she is Board Certified in Internal Medicine and Oncology.
Edward E. Partridge M.D.
Director, UAB Comprehensive Cancer Center
Professor of Gynecologic Oncology
Evalina B. Spencer Chair in Oncology
University of Alabama at Birmingham
Dr. Edward Partridge is a leading expert in Gynecologic Oncology, and currently is Co-Director, Co-Principal Investigator and Research Program Leader at Minority Health & Health Disparities Research Center, as well as Director, Professor of Gynecologic Oncology and Professor of Surgery at UAB Comprehensive Cancer Center. Dr. Patridge received his M.D. from the University of Alabama School of Medicine, and has Board Certifications in Gynecologic Oncology and Obstetrics & Gynecology. Among his many areas of research interest are Cancer Control and Prevention, Cervical cancer, community based research, gynecology oncology, minority health disparities, and ovarian cancer.
Oliver Sartor, M.D.
Laborde Professor of Cancer Research, Medicine and Urology Departments
Tulane School of Medicine
Tulane Cancer Center
New Orleans, Louisiana
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990, when he finished a medical oncology fellowship at the National Cancer Institute. He has published more than 300 articles and book chapters, and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular, he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely, and at last count had given invited lectures in 28 countries. He has served as the past chairman of the U.S. Department of Defense Prostate Cancer Integration Panel, is currently editor-in- chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counselors.
Bruce Chabner, M.D. (Ad Hoc Committee Member, former Executive Advisory Board Chair)
Chair, National Cancer Advisory Board
Director of Clinical Research
Massachusetts General Hospital Cancer Center
Dr. Chabner received his M.D. from Harvard cum laude in l965 and joined the National Cancer Institute (NCI) as a Senior Investigator in the Laboratory of Chemical Pharmacology in l971, he participated in the training of clinical and research fellows as Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program and its fellowship programs in medical, pediatric, radiation, and surgical oncology, and Director of the Division of Cancer Treatment, NCI. During this time, he maintained an active laboratory program in cancer pharmacology, focusing on the mechanism of action, and resistance of antifolates and other antimetabolites, and led the development of Taxol.
In 1995, Dr. Chabner joined Massachusetts General Hospital as Clinical Director of its cancer center and Chief of Hematology/Oncology. With the formation of the Dana-Farber/Harvard Cancer Center, he assumed responsibilities as Associate Director for Clinical Sciences of that consortium, which includes the Massachusetts General Hospital, Brigham & Women’s Hospital, Dana-Farber Cancer Institute and Beath Israel Deaconess Medical Center. Chabner authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers. He has received numerous awards for his work.
© 2017 USA Health System